Izizathu Zokufunda Okungamanga Ezivivinyweni Ze-Thyroid
Njengoba izimo eziningi zihlanganisa nesifo segciwane, sibheka izindinganiso ze-laboratory ukuqondisa ukwelashwa. Kodwa amanani we-lab angaba iphutha nganoma yisiphi isibalo sezizathu. Ngesifo se-thyroid, ukuhlolwa kwesifo se- hormone (TSH) ye-thyroid ebizwa ngokuthi yi-golden standard test yokuhlola umsebenzi we -roid kodwa akuyona into enembile ngaso sonke isikhathi. Futhi ukuphatha umzimba wakho ngokususelwa ekufundeni okungamanga kungabangela ukuzwa kabi.
Ama-antibodies ase-Heterophile acatshangwa ukuthi yisinye sezizathu zokufunda amanga kulezi zivivinyo. Yini okufanele uyenze ngamaphutha welebhu nemiphumela engavamile?
Izimbangela Zemibuzo Yokuhlola Engavamile Ngokujwayelekile
Ngenkathi sivame ukubuka izivivinyo ze-lab njengoba zingagcwaliseki zinikezwa ngezinombolo zomgomo wokukhonkolo, akuzona njalo. Eqinisweni, ngokusekelwe emathubeni okuphela kungenzeka ukuthi ube nomphumela wokuhlola noma amabili okungalungile empilweni yakho yokuphila.
Ngezivivinyo ze-thyroid, imbangela ebalulekile njengamanje icatshangwa ukuthi i-heterophile antibodies. Ake siqale ngokuxoxa ngalezi zinsizakuvikela, cabangela ezinye izizathu zokuhlolwa okungavamile, bese ukhuluma ngalokho ongakwenza nokuthi yini okufanele ukwazi ukuthi ungummeli wempilo yakho.
Ama-antibodies we-Heterophile kanye nemiphumela yokuhlola yamanga we-Thyroid
Ngo-2011, umhlangano waminyaka yonke wezi-endocrinologists waziswa ukuthi ama-antibodies angama-heterophile angafaka ingozi yemiphumela engalungile ekuhlolweni kwe-TSH.
Ama-antibodies ase-Heterophile ayaziwa nangokuthi an anti-animal antibodies futhi athuthukiswa ngenxa yokuvezwa kwezidakamizwa ezithathwe yizilwane kanye nemithi yokwelapha.
Ukuthuthukiswa kwama-antibodies e-heterophile kuvame kakhulu uma uthola ukuthelelwa igazi, ukugonywa, noma ngabe uye wadalwa izilwane ezithile (hhayi izifuyo zasendlini).
Akuqiniseki ukuthi amasosha omzimba we-heterophile ajwayelekile kangakanani, kodwa ukulinganisa kuyahluka kusuka kumaphesenti angu-80 ukuya kubantu abangamaphesenti angu-80. Ukungafani okubanzi kokusabalalisa kuhlobene nendlela i-antibody ekhonjiswa ngayo.
Ukwanda Kamuva Kwama-antibodies aseHeterophile
Okuphawula ukuthi ukubonakala kwama-heterophile antibodies kuye kwanda ngokuphawulekayo ngonyaka ka-2010. Ku-abstract okukhulunywe ngayo kulowo mhlangano, kwatholakala ukuthi amaphesenti angu-4.4 wamakhulu amasampula ahlolwe ahlushwa yi-anti-hemophile antibodies. Okukhathazeka okwengeziwe kwakuwukuthi i-TSH engavamile kufanele ihole ekuhloleni okuqhubekayo, kodwa ukuthi ukuhlolwa akukwenzeka njalo. Ngakho-ke, ukuba khona kwala ma antibodies kungaba nomthelela omkhulu.
Impact ye-Anti-Hedophile Antibodies
Umthelela wama-antibodies we-heterophile ungabonakala kakhulu kulezo zincumo zokwelashwa zenziwa njalo ngokususelwa ezingeni le-TSH . Izimpawu zicatshangwa kahle, kodwa izinga legolide ngokuvamile lihlala liyi-TSH. Lokho kusho ukuthi abantu abaphila nezinkinga ze-thyroid kumele bazi ukuthi lokhu kungaba nemiphumela engavamile.
Nini Ukumangalela Ama-Antibodies Heterophile
Njengoba i-TSH iyinqubo yegolide yokwenza izinguquko emithini yegciwane, ungazi kanjani ukuthi unamaphilisi a-heterophile anithinta amazinga akho?
Kubonakala sengathi ukungafani phakathi kwe-TSH ne-T4 yamahhala kuyimpawu. Noma ubani onayo izimpawu ezingavumelani nezimpawu zabo noma ezingalindelekile ngokusekelwe emlandweni wabo noma umthamo wamanje wemithi kufanele ube nokuhlolwa okwengeziwe.
Ezinye Izizathu Ezikhona Zokufunda Okungamanga Ezivivinyweni Ze-Thyroid
Ngaphandle kwama-antibodies we-heterophile, kunezindlela eziningi lapho ukuhlolwa kwelebhu kungakunika ukufundwa kwamanga kusuka kumaphutha egazini lakho ukudweba ekuhlanganiseni kulabhu, amaphutha ekubhaliseni izinombolo. Siyazi ukuthi amaphutha ezempilo ajwayelekile, futhi imbangela enkulu yokugula ngisho nokufa. Kungenzeka ukuthi izingqungquthela ezesabekayo ezibiza amaphutha ezempilo ngenxa yesithathu ebangela ukufa ziphosokile, kodwa ngenxa yokuthi kwacatshangwa ukuthi ifulegi elibomvu liba ngummeli wakho futhi likhulume uma kukhona okubonakala kungakalungi kuwe.
Isibonelo, uma unezimpawu ze-hyperthyroidism kanye nezivivinyo zakho zamalebhu ubonisa ukuthi u-hypothyroid futhi ngokuphambene nalokho. Ngezinye izikhathi into engcono kakhulu okufanele uyenze iphinde iqhubekele ukuhlolwa kwelebhu, noma ucele ukuhlolwa okuhlukile okungase kubonakale ukungafani futhi kubonise iphutha elingenzeka.
Ukubaluleka Kwenkinga Kungase Kucatshangelwe
Nakuba ukulinganiswa kokutholakala kwama-antibodies e-heterophile kubonakala sengathi kuyanda, inkinga kungenzeka ukuthi ingabi nkulu njengoba kucatshangwa kuqala. Ezinye izazi ze-laboratory zithi izivivinyo eziningi zanamuhla ziqukethe ama-antibodies okuvimbela okuzoqeda inkinga ye-TSH ephakeme kakhulu. Kuze kube khona ukuvumelanisa okufanele wazi?
Lokhu kusho ukuthini kuwe
Ukwazi konke lokhu, yini ongayenza ukuze ube ngummeli wakho ekunakekeleni kwesifo sakho se-thyroid? Kungakhathaliseki ukuthi uhlobene nama-antibodies we-heterophile noma enye indlela yephutha lebhu, ukukhuluma nodokotela wakho uma uzizwa ukhululekile. Uma uye waphathwa nge-hypothyroidism isikhathi esithile, ungase uqonde ukuthi uzizwa kanjani uma umthamo wakho weyeza imithi kakhulu noma uphansi kakhulu. Uma ungazizwa kahle, yenza i-aphoyintimenti.
Uma uphathwa nge-hypothyroidism futhi ube ne-TSH ebuyela emuva ephakanyisiwe (ephakeme), kungenzeka ukuthi udokotela wakho uyokwandisa umthamo wakho we-hormone ye-thyroid esikhundleni. Uma amazinga akho ephakeme we-TSH, noma kunjalo, ngenxa yama-antibodies we-heterophile, ukwanda kwamanani kungabangela ukunqwabelana kwemithi kanye nokwelapha-okubangelwa i-hyperthyroidism . Ngezikhathi ezingavamile, lokhu kuye kwabangela i-thyrotoxicosis enzima ( isiphepho se-thyroid ).
Uma uzizwa kahle kumanyolo wakho wokufaka esikhundleni, futhi unomphumela wokuhlola we-TSH ophezulu, kufanele ubuze udokotela wakho futhi asebenzise ukuhlolwa kwe- Free T4 kanye ne-Free T3 , ukuze ahlole kabili ukuthi ahlobana yini nezinga eliphakeme le-TSH.
Uma Ungenalo Isifo Sengculazi Futhi Unayo I-TSH Ephakeme
Uma ungatholakali unesifo se-thyroid futhi une-TSH ephakanyisiwe, kungaba kuhle ukuthi une-hypothyroidism. Phela, isifo se-thyroid sivame kakhulu. Ngesikhathi esifanayo, ungaba ne-heterophile antibodies ebangela ukuphakama futhi kungase kube ukuxilongwa okungafanelekile.
Uma lokhu kwenzeka kuwe, cela udokotela wakho ukuba agijime u-T4 mahhala futhi avikelele ukuhlolwa kwe-T3 ukuze uqinisekise ukuthi uhlolwe yini nge-hypothyroidism. Ngaphandle kwalesi sheke, ungase utholakale ngephutha nge-hypothyroidism futhi uqale ekwelapheni okubangelwa imithi-eyenziwa yi-hypothyroidism.
Ngezansi kuma-antibodies ase-Heterophile nezivivinyo ze-TSH zamanga
Akucaci ukuthi izifo ezivamile ze-heterophile zingabantu abaningi, kodwa uma zikhona zingabangela izinga eliphezulu le-TSH eliphakeme (kwezinye izilinganiso kodwa hhayi kwabanye). Ukwelashwa okusekelwe ezingeni le-TSH kuphela kungabangela i-hyperthyroidism eyenziwe ngemithi yokwelashwa kokubili labo abaphathwa nge-hypothyroidism nalabo abaphazamiseka ngephutha nge-hypothyroidism esekelwe ekuhlolweni.
Uma i-TSH yakho iphakanyisiwe futhi ungenayo izimpawu ze-hypothyroidism (uma uzizwa uhle) cela udokotela wakho ukuthi ahlole i-T4 yamahhala futhi i-T3 ikhululekile ukuze iqondanise izinombolo zakho futhi ibheke ukungavumelani.
> Imithombo:
> I-American Thyroid Association. Umhlangano Wonyaka Wama-81. Abstract 103. 2011.
> Chin, K., ne-Y. Pin. I-Heterophile Antibody Ingxube Ye-Assay ye-Thyroid. Imithi yangaphakathi . 2008. 47 (23): 2033-7.
> Lewndowski, K. Odd Imiphumela YemiSebenzi Yomsebenzi We-Thyroid: Ukungafani nokungahambisani Nokuthobela. Ucwaningo lwe-Thyroid . 2013. 36 (Isihlomelo 2): A37.
> Ukwehluleka kwemvelo, S. Fulminant Ukuhluleka Kwebindi Okuhlanganiswa Nokubambezeleka Kwethambo le-Thyroid ngenxa yama-Antibodies aseHeterophile. Isifo sikashukela kanye ne-Endocrinology . 2015. 1:12.
> Srichomkwun, P., Scherberg, N., Jaksic, J., noS S. Refetoff. I-Diagnostic Dilemma Ezingavumelani Nemisebenzi Ye-Thyroid Yezinyathelo Ngenxa Yama-Hormone Autoantibodies we-Thyroid. Imibiko Yesikhungo Se-AACE Clinical . 2017. 3 (1): e22-e25.